Less than one in 10 individuals eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it publishes its initial advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for more widespread and fairer access to GLP-1 medication.
According to forecasts, over two billion are projected to be obese by 2030 without intervention.
"The new guidelines affirms that excess weight is a chronic disease that can be addressed with comprehensive and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to widespread access to the treatments that can aid individuals in losing significant weight, says the body.
Weight-Loss Drug Scarcity
Despite the present best projected outlook, the production of these medications might only reach approximately 100 million people – fewer than 10% of those who need them, according to the WHO.
The advice urges nations and manufacturers to expand access, by approaches such as patent sharing.
The intellectual property rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs mimick a natural hormone to slow digestion, curb appetite and enhance satiety so people eat less.
Individuals typically begin shedding pounds in the initial weeks of commencing the regular doses.
Studies suggests users may see weight return a year later of stopping the treatment, because their usual hunger come back.
Being above a healthy weight elevates your chance for experiencing health problems, such as type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight concerns people in all nations and was linked to millions of deaths worldwide in 2024, according to the WHO.
